Panbela Therapeutics, Inc. Company profile
About Panbela Therapeutics Inc
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing disruptive therapeutics for the treatment of patients with cancer. The Company is engaged in the commercial development of a polyamine analogue for pancreatic cancer. Its product candidate includes SBP-101, which is a proprietary polyamine analogue that accumulates in the exocrine pancreas acinar cells due to its chemical structure. The Company is conducting Phase I a/I b study of the safety, efficacy and pharmacokinetics of SBP-101 administered in combination with two standard-of-care chemotherapy agents, gemcitabine and nab-paclitaxel.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Panbela Therapeutics Inc revenues was not reported. Net loss increased 70% to $6.6M. Higher net loss reflects Research and Development - Balancing increase of 90% to $3.2M (expense), General and administrative -Bal increase of 69% to $2.5M (expense), Other income decrease from $55K (income) to $611K (expense).
Latest shares articles
![](https://img.capital.com/imgs/articles/384x2000x0/1350x880_-HP-_Newsquawk-light_1.png)
![Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/384x2000x0/Hero-image-bank_1.png)
![Exterior of Infosys headquarters](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_2035197281_0_0.jpg)
![Tesla logo atop of a Tesla Dealership illuminated at night.](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_1494516293_0.jpg)